There were fewer cardiac events at 2 years for MI patients with LVEF 40% to 49% discharged on beta blockers and, separately, renin-angiotensin-system inhibitors in a propensity-matched cohort study.
The expanded indication for the SGLT2 inhibitor empagliflozin (Jardiance) now includes heart failure with mid-range or preserved left-ventricular ejection fraction essentially all heart failure.
Understudied but at risk, patients with preserved-EF heart failure but normal levels of the biomarker are in some ways intermediate between those with no HF and those with HFpEF and high NT-proBNP.
A large, multicenter cohort study supports phenotype-based screening of first-degree family members of patients with confirmed DCM without input, necessarily, from genetic testing.
The trial was neutral but said to have produced important mechanistic insights that could guide the investigational heart failure device therapy to success in the future.